Resuming Fosamax After Tooth Extraction
Patients can resume Fosamax (alendronate) immediately after tooth extraction when proper surgical protocols are followed, though a conservative approach of waiting 2-4 weeks until initial soft tissue healing is complete may be prudent for patients at higher risk of complications.
Key Considerations for Timing
Standard Risk Patients
- No mandatory drug holiday is required for routine tooth extractions in patients taking oral bisphosphonates like Fosamax 1, 2.
- Alendronate can be continued or resumed immediately after extraction when:
Evidence Supporting Early Resumption
- A large retrospective study of 221 patients undergoing 639 tooth extractions while on bisphosphonates showed zero cases of medication-related osteonecrosis of the jaw (MRONJ) when extractions healed by secondary intention with appropriate protocols 2.
- Research demonstrates that short-term alendronate treatment does not impede bone formation in extraction sockets and may actually enhance bone healing 3.
- Animal studies show alendronate causes only transient delays in early healing (10 days post-extraction) but does not affect long-term socket healing 4.
Risk Stratification Approach
Lower Risk Profile (Can Resume Immediately)
- Oral bisphosphonate use (vs. IV) 1
- Duration of therapy <5 years 5
- Simple, atraumatic extraction 2
- No local risk factors (infection, trauma, poor oral hygiene) 2
- No systemic risk factors (diabetes, smoking, immunosuppression) 2
Higher Risk Profile (Consider 2-4 Week Delay)
- IV bisphosphonate therapy 6
- Concurrent corticosteroid use (significantly increases MRONJ risk) 6
- Complex surgical extractions requiring bone removal 2
- Multiple extractions in one session 2
- History of radiation to jaw or previous MRONJ 1
Critical Surgical Protocols
These protocols are essential regardless of when alendronate is resumed:
- Antibiotic coverage: Prophylactic antibiotics before and after extraction 2
- Anesthetic selection: Use local anesthetics without vasoconstrictors 2
- Surgical technique: Minimally invasive approach, avoid excessive bone trauma 2, 7
- Wound management: Allow healing by secondary intention with chlorhexidine rinses 2
- Follow-up: Close monitoring for signs of delayed healing or exposed bone 1
FDA Labeling Guidance
The FDA label for Fosamax warns about osteonecrosis of the jaw as a known risk but does not specify a mandatory drug holiday period for dental procedures 1. The label emphasizes:
- ONJ risk is associated with bisphosphonates, particularly with invasive dental procedures 1
- Patients should maintain good oral hygiene 1
- Dental examination with appropriate preventive dentistry should be considered prior to treatment 1
Common Pitfalls to Avoid
- Prolonged drug holidays are not evidence-based: Extended discontinuation (>3-6 months) may increase fracture risk without proven benefit for ONJ prevention, as bisphosphonates remain in bone for years 5, 1.
- Ignoring combination therapy risks: Patients on both bisphosphonates and corticosteroids have substantially higher MRONJ risk and warrant more conservative management 6.
- Poor surgical technique: Traumatic extractions with excessive bone manipulation increase ONJ risk more than the medication itself 2.
- Inadequate antimicrobial coverage: Failure to use prophylactic antibiotics and chlorhexidine increases infection risk 2.
Duration of Therapy Considerations
For patients who have completed 3-5 years of alendronate therapy for osteoporosis, consider whether continued treatment is necessary before resuming after extraction 5, 1. The American College of Physicians recommends treating osteoporotic women for 5 years, then reassessing the need for continued therapy 5. This extraction may provide an opportune time for that reassessment.